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ABSTRACT
Objectives Determining the cost-effectiveness of enzyme replacement therapy 
(ERT) for the classical infantile form of Pompe disease (complete acid α-glucosidase 
defi ciency-related) in two different settings: England and Colombia. Pompe disease 
is very rare (1:40,000 births incidence). 
Methods A literature review was made and historic databases searched for 
National Health Service (NHS) reimbursed costs in England and by health insurers 
in Colombia; expert opinion was elicited. Two Markov models were constructed 
for comparing both countries; alive with symptoms and dead were the transition 
states used.  Patients aged ≤ 6 months receiving ERT were assumed to have 75 % 
survival rate and better health-related quality of life (HR-QoL) compared to those 
without treatment (0.700 HR- QoL using the EQ-5D scale).
Results The incremental cost-effectiveness ratio (ICER) per quality-adjusted life 
year (QALY) gained was £234,307.7 for England and £109,991 for Colombia. 
Uncertainty about fi nal HR-QoL with ERT, disease progression and cost from 
palliative care had the biggest impact on the ICER in both models. If ERT costs 
were reduced to 10,000 times per dose and HR-QoL was 0.750-0.820 ICER, then 
£165,000 could be attainable for England and £65,000 for Colombia. Transaction 
costs per case in Colombia were high. 
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Conclusions ERT was more effective than no ERT in treating infantile Pompe 
disease, but high levels of uncertainty still remain about survival and progression 
rates and QoL in the long-run. ICERs were high compared to CE thresholds. 
Manufacturers’ ERT costs and monopoly had a major impact on fi nal CEA results.
Key Words: Glycogen storage disease type II, Pompe disease, cost and cost 
analysis, cost- benefi t analysis, quality of life (source: MeSH, NLM). 
RESUMEN
Objetivo Determinar la costo-efectividad de la TRE como indicación para la 
forma clásica de la enfermedad de Pompe (relacionada con defi ciencia completa 
de α-glucosidasa ácida) desde dos perspectivas, Inglaterra y Colombia. La 
enfermedad de Pompe es muy rara (incidencia 1:40000 nacimientos). 
Métodos Revisiónbibliográfi ca y bases de datos para calcular costosasociados al 
tratamiento en NHS en Inglaterra, aseguradores de salud en Colombia y opinión 
de expertos. Dos procesos de Markov fueron construidos para comparar entre 
países; los estados de transición fueron: vivo sintomático y fallecido. En pacientes 
de  ≤ 6 meses de edad con TRE, se asume un incremento de 75 % de sobrevida 
y mejor calidad de vida comparada con los que no reciben TRE (HR-QoL 0.700 
usando EQ-5D). 
Resultados Inglaterra alcanzo ICER por QALY ganado £234307, 7 y Colombia 
£109991. Incertidumbre sobre HR-QoL con TRE, progresión de enfermedad y 
costo de cuidado paliativo tuvieron el mayor impacto en losICERs;sí el costo de 
TREfuera 10.000 menor y la HR-QoLalcanzara 0.750-0.820 ICERs de £165000y 
£65000 podrían obtenerse para Inglaterra y Colombia respectivamente. Los costos 
transaccionales en Colombia son representativos. 
Conclusiones La TRE es más efectiva que no dar tratamiento, pero incertidumbre 
sobre tasas desobrevida, progresión y HR-QoLpermanecen en el largo plazo. Los 
ICERsson altos comparados a los umbrales establecidos de CE. Los costos de 
TRE y el podermonopolístico del fabricante tienen un impacto importante en los 
resultados fi nales de CEA. Investigación adicional debe realizarsea futuro.
Palabras Clave: Enfermedad de Almacenamiento de Glucógeno Tipo II, 
glucogenosis generalizada, Glucogenosis 2, Enfermedad por Defi ciencia de 
Maltasa Ácida, Enfermedad de Pompe, Enfermedad por Defi ciencia de Lisosoma 
alfa-1,4-Glucosidasa, defi ciencia de maltasa ácida, análisis costo- benefi cio, costo 
efectividad, calidad de vida (fuente: DeCS, BIREME).
Pompe disease is a very rare autosomal recessive disorder which was fi rst described in 1932 by JC. Pompe (a Dutch pathologist); it is also known as acid maltase defi ciency or glycogen storage disease type II 
(1). The disease is characterised by acid α-glucosidase defi ciency leading 
to progressive glycogen accumulation in cardiac, skeletal and respiratory 
muscle tissue which could result in cardio-respiratory defi ciency and death. 
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There are two clinical forms of the disease, the classical infantile form 
which is usually lethal and related to complete α- glucosidase defi ciency and 
the milder and later onset form that may present at any age (sub-categorised as 
non-classical infantile, childhood, juvenile and adult) usually related to partial 
enzyme defi ciency (1–4).
The incidence of all combined forms of Pompe disease is 1:40,000 births 
worldwide (5,6). It is not precisely known how many people suffer from it, but 
it has been assumed that no more than 5,000–10,000 people worldwide are 
affected. It occurs in people of all races, but occurs more frequently in African 
Americans (1/14,000 births cf 1/60,000 adults and 1/100,000 Caucasian 
children) (7). Consequently, Pompe disorder has been classifi ed as an orphan 
disease, such denomination being used for rare conditions (less than 200,000 
people in North-America and no more than 5 in 10,000 in Europe).
Feeding problems, failure to gain weight, muscular weakness, motor 
development impairment, cardiac problems, respiratory diffi culty and airway 
infections are frequently reported as being the main symptoms during the fi rst 
months of life (mean 1.9- 2.1 months) and most infants die within the fi rst 
year (92-95 %) usually after a short period of inpatient care (median 2.8- 4.0 
months) from cardiorespiratory insuffi ciency (7,8).
Late-onset Pompe disease predominantly presents as a slowly progressive 
proximal myopathy affecting young and middle aged individuals; the 
symptoms are mostly related to mobility problems and limb girdle weakness, 
such disability varying amongst patients. Diagnosis is not straightforward and 
may take more than 5 years in up to 28 % of patients (8).
Treatment was merely palliative and supportive before enzyme replacement 
therapy (ERT) was introduced; however, a recombinant α-glucosidase 
(myozyme) was approved in 2006 as the fi rst and only drug to be used for 
enzyme replacement. Evidence showed that -glucosidase signifi cantly 
prolonged total and ventilator-free survival in patients suffering from the 
classical infantile form. Patients with severe defi ciency and early onset of 
enzyme defi ciency (before 6 months of age) seem to have shown the most 
marked benefi t (9).
A 20mg/kg ERT scheme every two weeks is expected to increase survival 
rates per year from 73 % (45-92, 95 % CI) to 89 % (68-100, 95 % CI) according 
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to some clinical studies (10). Cox proportional-hazards regression models 
have shown that -glucosidase has reduced the risk of death by 99 % (0.01 
hazard ratio; 0.00-0.10 95 %CI; p<0.0001) in patients aged ≤ 6 months and 
71 % (hazard ratio: 0.29; 0.11-0.81 95 % CI; p<0.018) for patients aged > 
6 months to ≤ 36 months.-glucosidase-treated patients had improved their 
cardio-myopathy, growth, weight gain, motor development and functional 
status. According to the manufacturer at least 76 % survival rate is expected for 
patients aged < than 6 months who are being treated. No long-term assessment 
of health-related quality of life (HR-QoL) has been made for live patient 
populations receiving ERT. 
Although all patients treated with myozyme could develop adverse 
events from treatment, the commonest mild to moderate adverse reactions 
requiring intervention have been infusion-related (up to 51 % of cases during 
the 2 hours following infusion); clinical trials and post-marketing safety 
experience with myozyme have shown that about 1 % of patients developed 
anaphylactic shock and/or cardiac arrest during myozyme infusion requiring 
life-support measures and another 14 % have developed other major allergic 
reactions.
METHODS
Two Markov models from were constructed from a health system’s perspective 
based on patient transition state (alive-symptomatic and dead); since the 
disorder is always progressive and symptomatic after being diagnosed, 
no alive-asymptomatic transition state was considered. ERT was assumed 
to partially restore patients’ quality of life (QoL). Motor development 
impairment and respiratory insufficiency progression were expected to occur 
in the model in the long-run. 
Most parameters for populating the models were derived from published 
literature. Each cycle was considered to be yearly based and the model was 
run for 20 cycles from experts’ opinion regarding expected life expectancy 
(9). Discount rates were 5 % for both costs and effects in each cycle. 
Effectiveness was calculated in quality-adjusted life years (QALY) gained 
and cost in 2010 GBP (£). Markov models were run using TreeAge pro 2009.
Eight studies were reviewed concerning the natural course of disease; one 
of the main comparative reviews of historic cohorts came from a 2003 Dutch 
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study (8) which gave a 92 % mortality rate (109/119) during the fi rst year 
of life after birth for children suffering Pompe disease and who received no 
ERT. Some assumptions were made when constructing the decision model. 
Since death usually occurs after a 78 day period of inpatient palliative and 
supportive care, such average length of stay was introduced and multiplied 
by average cost per day in calculating the average cost of supportive and 
palliative care, assuming that all patients would be placed in an intensive care 
unit (ICU) before death. Two other studies determined ERT effectiveness 
rate, assuming a 75 % survival rate per year for this model (9, 10).
Table 1. Cost related to Pompe disease treatment
Costs per cycle Average Units Total Total per patient (10Kg av. weight)
England     
PICU per diem £1.900.0 78 £148.200.0 £148.200.0
Complications from ERT (10 % overload)** £190.0 78 £14.820.0 £7.558.2
ERT α-glucosidase (20 mg/Kg every 2 
weeks)* £147.4 26 £3.832.4 £38.324.0
Non drug cost from application £10.0 26 £260.0 £260.0
Average cost £194.342.2
Colombia
PICU per diem £632.7 78 £49.350.6 £49.350.6
Complications from ERT (10 % overload)** £63.3 78 £4.937.4 £2.518.1
ERT α-glucosidase (20 mg/Kg every 2 
weeks)* £160.3 26 £4.167.8 £41.678.0
Non drug cost from application £12.0 26 £312.0 £312.0
Transaction costs (importation and 
logistics) £342.0 12 £4.104.0 £4.104.0
Average cost £97.962.7
 *Weighting derived from 5 % boys & girls (National Centre for Chronic Disease Prevention & 
Health Promotion, 2000); ** Complications from ERT 51%
Costs were calculated for inpatient palliative and supportive care in 
a paediatric intensive care unit (PICU). ERT was given every two weeks 
involving 20 mg/Kg myozyme doses (26 per cycle); ERT infusion non-drug 
costs and the cost of treating complications arising from ERT application 
were also included. A 51 % probability for complications arising from 
ERT application was included (11) and 10 % extra was loaded for inpatient 
care assuming that any complication would require extra care should 
complications arise. Assuming a marked deviation from normal weight gain 
curves for boys and girls with Pompe disease, 5 % weight was used as a 
reference for calculating total ERT dose per case (12). 
REVISTA DE SALUD PÚBLICA · Volumen 14 (1), Febrero 2012148
All costs related to diagnosis were not included, assuming that children 
would enter the model after being diagnosed and average outpatient 
specialist’s consultations were assumed to be similar for both groups as 
disease progression would mostly likely lead to them being treated as 
inpatients, hence costs related to out-patient care other than ERT infusion 
were neglected. Inpatient care costs, ERT cost and costs from treating 
complications from ERT application in England were obtained from 
National Health Service (NHS) and healthcare resource group (HRG) 
sources, parliament reports and the British National Formulary for Children 
(BNF-C) for different years. Non-drug ERT application costs were obtained 
from a 2003 Dutch study (13).  All costs were calculated at 2010 prices, 
using infl ation rates reported by the UK Offi ce for National Statistics (14, 
15). Average costs incurred by third-party payers from the Colombian Social 
Health Insurance Scheme (SHI) were calculated; COOMEVA EPS, one of 
the biggest insurers, shared historical data regarding average inpatient care, 
ERT, non-drug and ERT treatment complication costs. They were adjusted 
to  2010 values according to the Colombian Statistics Department (DANE) 
infl ation fi gures and exchanged from Colombian pesos to British Pounds to 
ease comparison (16,17). An extra £ 4,104 cost per cycle was added to the 
Colombian model arising from third-party payers’ importation costs and 
logistics (£ 342 per month). Table 1 gives a summary of costs. 
Three scenarios were assumed for classifying symptomatic patients 
still alive and suffering from Pompe’s disease. EuroQol Group’s EQ-5D 
would give the worst-off state scenario as being health state 22 322 (0.189 
utility value), 22 221 middle state (0.587 utility value) and 21 211 best-
off state (0.814) (18). Since there was a 50 % chance of moving from 
best-off or middle state to worst-off state (with or without ERT), two 
main health states were combined (0.189*0.5) + (0.587*0.5)=0.388 and 
(0.587*0.5)+(0.814*0.5)=0.700 (18). Assuming that ERT would favour 
higher HR-QoL, the higher combined value was assigned to being alive 
with ERT and the lower value to being alive without ERT. 
RESULTS
No ERT gave £149.178 per 0.16 QALYs gained and ERT £1,337.118 per 
5.23 QALYs gained after 20 years in the English model; the incremental 
cost-effectiveness ratio (ICER) per QALY incremental cost-effectiveness 
ratio was £234,307.7. 
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Figure 1. Markov model
Table 2a. Incremental cost effectiveness ratio - England







ICER per QALY 
gained
No ERT £149.178 0.16 0.388
ERT £1337.118 5.23 0.700 £1187.940 5.07 £234.308
No ERT resulted in £49.676 per 0.16 QALYs gained and ERT £607.329 
per 5.23 QALYs gained after 20 years in the Colombian perspective model; 
the ICER per QALY was £109,991.
Both one-way and two-way sensitivity analysis were used for refl ecting 
alternative structural assumptions.
Table 2b. Incremental cost effectiveness ratio - Colombia










No ERT £49,676 0.16 0.388
ERT £607,329 5.23 0.700 £557,653 5.07 £109,991
Sensitivity analysis 1. ERT would have a differential impact on health 
state.  ERT may not resolve all disease symptoms and patients may 
remain, at least, in a mild disease state. All patients were assumed to have 
0.700 QoL with ERT treatment in the present model. Some literature has 
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shown that cardiac hypertrophy may become resolved after ERT but other 
complications like inability to achieve normal motor development, feeding 
problems and mild respiratory symptoms may persist or even progress, 
thereby having an expected impact on HR-QoL value. HR-QoL could be 
much lower than expected if glycogen deposits continue, even with ERT. 
Sensitivity analysis 1 included 0.100 to 0.900 utility values. ERT ICER 
substantially decreased the more optimistic the assumption was about HR-
QoL. The ICER was nearly to £180,000 in the English model at 0.900 and 
sloped to £2,015,000 when the value was 0.100. The Colombian ICER was 
0.900 close to £85,000 and sloped up to nearly £946,000 when the value 
was 0.
Analysis 2. Changes in drug cost. ERT is a relatively costly treatment. 
Base-case analysis estimated that a patient would cost £3,833 annually per 
Kg for England and £4,166.5 for Colombia. Sensitivity analysis 2 revealed 
the extent to which ERT unit cost drives the cost-effectiveness model. The 
cost per Kg varied between £0 and the fi nal estimates included for each 
country. The results showed a mild impact on ICER ranging from £200,000 
at £0 cost per Kg up to £234,000 at actual cost in England and from £73,000 
at cost per Kg of £0 up to £110,000 at actual cost in Colombia.
Analysis 3. Additional transaction costs being faced by the Colombian 
health system and derived from additional importation and transportation 
costs. Ranging from £0 up to £41,040 (10 times the actual importation cost 
of £4,104), transaction costs were hypothetically simulated and increased 
this result so that ICER fell from its actual £110,000 to £104,000 at no 
importation cost and ICER would increase up to £164,000 if importation 
cost rose 10 times. Analysis 4. Cost of treatment compared to Effectiveness. 
Two-way sensitivity analysis showed that if ERT costs were 10,000 times 
lower (nearly £0.38 for England and £0.41 for Colombia), ICER would 
become decreased to £165,000  for  England and £65,000 for Colombia, 
but only if the utility derived from treatment (HR-QoL) reached at least 
0.820 for England and 0.750 for Colombia. Monte Carlo simulation was 
used for probabilistic sensitivity analysis (PSA) to emulate a cohort of 
1,000 patients with Pompe disease being treated with ERT and no ERT.
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DISCUSSION
Clinical evidence supports the clinical effectiveness of ERT with 
-glucosidase (myozyme) in the short-run for patients suffering the early 
onset (classical) form of Pompe disease. Survival rates during the first year 
of life would be expected to improve from 8 % without treatment to 40 
% and even closer to 100 % with ERT; decreased cardiac hypertrophy, 
major milestones regarding motor development and later progression of 
respiratory insufficiency could increase life expectancy at birth for this 
population by up to at least 20 years according to experts’ opinion (1-3,8,9).
 
In spite of such optimistic fi ndings, there is still very limited evidence 
and lack of long-term data to prove that HR-QoL would be close to life lived 
in full health (a utility value of 1), or if patients receiving ERT could live a 
productive and less-dependent life. Disease progression rate with ERT has 
not been suffi ciently studied and it may be the case that the more severe the 
disease, the greater the chances of demanding costly inpatient and intensive 
palliative care with its subsequent negative impact on the model’s results. 
If Pompe disease could be stabilised by ERT or even regressed, then a new 
transitional state of being alive and asymptomatic whilst receiving ERT 
could be introduced into future models. 
Two models were run to compare a high income country (England) having 
a taxation-based health system, a single payer (the NHS), a strong culture 
and  health technology assessment (HTA) with  a middle income country 
(Colombia) having a social health insurance scheme, many purchasers and a 
very recent history of HTA. An additional difference and paradoxical fi nding 
was that average ERT cost per case in Colombia might be 9 % more costly 
than in England, probably from health insurers’ segmented purchasing power 
compared to a stronger monopsonistic purchaser in the UK (associated with 
additional £4,104 transaction importation and nationalisation costs per case). 
ICERs per QALY were still very high in both cases, £234,000 in England 
and £90,000 in Colombia compared to “established” cost-effectiveness 
thresholds per QALY or YL gained as decision rules in some other countries 
[for instance £30,000 in the UK, USD$50,000 in the USA, NZ$20,000 in New 
Zealand, US$69,000 in Sweden, AU$ 42,000 in Australia and so on](19,20), 
especially as low income (LIC) and middle income (MIC) thresholds have not 
been set or discussed by their societies (19). However, it is clear that healthcare 
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decisions are not made on the appeal of arbitrary numbers; cost-effectiveness 
thresholds are still objective national benchmarks related to each society’s 
affordability criteria. 
The results from this model agreed with those of Scottish NHS 2007 
(Scottish Medicines Consortium) where cost per QALY gained for children 
≤6 months was £244,450; this 2010 version was £234,308 per QALY gained 
(England). SMC advice in 2007 was not to recommend using -glucosidase 
(myozyme) in Scotland for treating Pompe disease (9). Nevertheless, this 
model’s level of correspondence had several limitations, basically because of 
limited data sources. Real worldwide disease prevalence is not clear, utility 
values for different states of the disease (mild, moderate or severe) with or 
without ERT have not yet been elicited. EQ-5D despite having cultural and 
geographical differences was applied in both models to assign values; using 
expert preferences, a child-friendly version of EQ-5D might be more suitable for 
elucidating patients’ preferences. Uncertainty about future clinical attainment 
or deterioration still remains. It was also assumed that as chronic disease 
impact on weight gain will be persistent, then a 5 % percentile line was used 
throughout; however, it is unclear if weight gain curves would become closer 
to normal distribution following chronic ERT treatment. Probability of death 
following anaphylactic shock from ERT application was calculated at 50% (1 
% overall risk). It was also assumed that since Pompe disorder is progressive 
and once diagnosed it is always symptomatic, no alive-asymptomatic transition 
state was considered. Costs from diagnostic phase and out-patient care were 
seen as irrelevant due to coinciding with previous economic studies concerning 
lysosomal storage disorders (LSD) (21). Additional limitations were related 
to infl ation rates and trends for both countries, and the possible impact on 
currency exchange rates that the ongoing economic crisis may have had on 
international and pharmaceutical markets. 
This analysis ran two comparative models to assess ERT cost-effectiveness 
with -glucosidase for the classical infantile from of Pompe disease. The 
results showed that ERT was clinically more effective than no ERT in treating 
the disorder but high levels of uncertainty still remain about life expectancy, 
survival rates, progression and quality of life regarding long-term treatment. 
ICER gave £234,000 for England and £110,000 for Colombia, such 
fi gures still being very high compared to tacit or explicit international 
decision-making thresholds. Costs related to inpatient and palliative care 
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had the greatest expected impact on overall costs due to the aggressive 
natural course of disease. Pompe disease treatment is categorised as orphan 
drug treatment, therapeutical options are still limited and costs related to 
research and developing new medicines high, hence manufacturers’ prices 
and monopolistic power still have a large impact on fi nal CEA results; 
paradoxically, MIC might be facing higher fees than HIC when reimbursing 
-glucosidase. Issues related to fragmented purchasing power and context 
regulation should be born in mind when assessing the evidence in detail. 
Comparing different countries’ perspectives is not about what is right 
and wrong but about informing what can be learned from one setting to 
another. Since HTA does not travel well across borders, local data becomes 
essential in decision-making and it seems there is ample space for further 
research in this fi eld in developing countries. CE thresholds become 
benchmarks whenever budgetary constraints hamper/support decision-
making, but they need to be used alongside other social and technical tools. 
Since there are no clinical comparators for ERT other than supportive 
and palliative care for Pompe disease, further economic evaluation should 
include considering the real costs of inpatient and out-patient care for both 
patients with and without ERT. Ethical considerations will only allow 
comparisons with historic non-ERT cohorts and patients receiving ERT; 
a big enough international sample of patients treated with -glucosidase 
might be hard to obtain and expensive, hence economic modelling appears 
to be a useful research tool for assisting decision-makers. 
Patients around the world are receiving treatment regardless of 
sustainability and lack of data regarding long-term QoL with ERT, 
so additional research, especially from broader perspectives than the 
purchaser’s, is advisable to ensure awareness about broader societal aspects 
of treatment to report on potential social welfare losses or gains when ERT 
is used in the long-run ♦
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